Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily

Journal of Biotechnology

Volumn 172, Issue 1, 2014, Pages 73-76

  Hemmerle, Teresa ^a   Hess, Christian ^a   Venetz, Dario ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

F8 antibody; FasL; TRAIL; Tumor necrosis factor superfamily; Vascular targeting

Indexed keywords

ANTICANCER ACTIVITIES; FASL; FUNCTIONAL PROPERTIES; IMMUNOLOGICAL FUNCTIONS; INFLAMMATORY RESPONSE; TRAIL; TUMOR NECROSIS FACTORS; VASCULAR TARGETING;

GLYCOPROTEINS; MACROPHAGES; MONOCLONAL ANTIBODIES; PROTEINS;

TUMORS;

ANTIBODY FUSION PROTEIN; CD40 LIGAND; CYTOKINE; FAS LIGAND; FIBRONECTIN; LIGHT PROTEIN; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN BETA; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F8; PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; EMBRYONAL CARCINOMA STEM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RADIOACTIVITY; RADIOIODINATION; TERATOCARCINOMA; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

F8 ANTIBODY; FASL; TRAIL; TUMOR NECROSIS FACTOR SUPERFAMILY; VASCULAR TARGETING;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; CELL LINE; CHO CELLS; CRICETULUS; FAS LIGAND PROTEIN; FEMALE; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; MICE; MICE, 129 STRAIN; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTORS;

EID: 84892654619     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2013.12.010     Document Type: Article

References (33)

1. Badran A., Asano R., Nakayama M., Watanabe Y., et al. Target cell-restricted apoptosis induction by 528scFv-TRAIL fusion protein specific for human EGFR and expressed in Escherichia coli. Int. J. Oncol. 2010, 36:1229-1230.
2. Balza E., Mortara L., Sassi F., Monteghirfo S., et al. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 2006, 12:2575-2580.
3. Borsi L., Balza E., Bestagno M., Castellani P., et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 2002, 102:75-85.
4. Borsi L., Balza E., Carnemolla B., Sassi F., et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4390.
5. Bremer E., Samplonius D.F., van Genne L., Dijkstra M.H., et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 2005, 280:10025-10030.
6. Bremer E., van Dam G.M., de Bruyn M., van Riezen M., et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol. Ther. 2008, 16:1919-1920.
7. de Bruyn M., Rybczynska A.A., Wei Y., Schwenkert M., et al. Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol. Cancer 2010, 9:301.
8. de Bruyn M., Wei Y., Wiersma V.R., Samplonius D.F., et al. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells. Clin. Cancer Res. 2011, 17:5626-5630.
9. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., et al. The clinical trail of TRAIL. Eur. J. Cancer 2006, 42:2233-2240.
10. Ebbinghaus C., Ronca R., Kaspar M., Grabulovski D., et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 2005, 116:304-313.
11. Ferrari S., Casali P., Blay J., Tonini G., et al. Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS). J. Clin. Oncol. 2013, 31.
12. Gafner V., Trachsel E., Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int. J. Cancer 2006, 119:2205-2210.
13. Halin C., Niesner U., Villani M.E., Zardi L., Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer 2002, 102:109-116.
14. Hehlgans T., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20.
15. Hemmerle T., Wulhfard S., Neri D. A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data. Protein Eng. Des. Sel. 2012, 25:851-854.
16. Hemmerle T., Probst P., Giovannoni L., Green A., et al. The antibody-based targeted delivery of TNF in combination with doxorubicin cures sarcomas in mice and confers protective immunity. Br. J. Cancer 2013, 109:1206-1213.
17. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28:2839-2840.
18. Hess, C., Venetz, D., Neri, D., Emerging classes of armed antibody therapeutics against cancer, MedChemComm, in publication.
19. Kontermann R.E. Antibody-cytokine fusion proteins. Arch. Biochem. Biophys. 2012, 526:194-205.
20. Lejeune F.J., Lienard D., Matter M., Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006, 6:6.
21. Lorusso D., Scambia G., Amadio G., di Legge A., et al. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br. J. Cancer 2012, 107:37-42.
22. Melkko S., Halin C., Borsi L., Zardi L., Neri D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:1485-1490.
23. Niesner U., Halin C., Lozzi L., Gunthert M., et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug. Chem. 2002, 13:729-736.
24. Pasche N., Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov. Today 2012, 17:583-590.
25. Pasche N., Wulhfard S., Pretto F., Carugati E., Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with Paclitaxel. Clin Cancer Res 2012, 18:4092-4103.
26. Pfeffer K. Morphogenic and host protective functions executed by tumor necrosis factor receptors, lymphotoxin receptors and their ligands. Eur. Cytokine Netw. 2000, 11:514.
27. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003, 14:185-191.
28. Samel D., Muller D., Gerspach J., Assohou-Luty C., et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 2003, 278:32077-32082.
29. Stieglmaier J., Bremer E., Kellner C., Liebig T.M., et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol. Immunother. 2008, 57:233-246.
30. ten Cate B., Bremer E., de Bruyn M., Bijma T., et al. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23:1389-1390.
31. Villa A., Trachsel E., Kaspar M., Schliemann C., et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int. J. Cancer 2008, 122:2405-2413.
32. Ware C.F. The TNF Superfamily-2008. Cytokine Growth Factor Rev. 2008, 19:183-186.
33. Wiersma V.R., He Y., Samplonius D.F., van Ginkel R.J., et al. A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. Br. J. Haematol. 2013, 164:304-307.